Cimzia

Certolizumab pegol

Monoclonal antibody
Type	Fab' fragment
Source	Humanized (from mouse)
Target	TNF alpha
Clinical data
Trade names	Cimzia
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a608041
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Subcutaneous
ATC code	L04AB05 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Biological half-life	about 11 days
Excretion	Renal (PEG only)
Identifiers
CAS Number	428863-50-7 N
ChemSpider	none
UNII	UMD07X179E
KEGG	D03441 Y
ChEMBL	CHEMBL1201831 N
Chemical and physical data
Formula	C2115H3252N556O673S16
Molar mass	47,750 g/mol
NY (what is this?)

Certolizumab pegol (CDP870, tradename Cimzia) is a biologic medication for the treatment of Crohn's disease,rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.

Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.

Significant side effects occur in 2% of people who take the medication.

...
Wikipedia